Pharmacotherapy of Autism and related disorders

Psychiatric Annals

Volumn 40, Issue 4, 2010, Pages 203-209

  Blankenship, Kelly ^a   Erickson, Craig A ^a   McDougle, Christopher J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77951729952     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/00485713-20100330-06     Document Type: Article

References (40)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders [text revision]. 4th ed. Washington, DC: American Psychiatric Publishing; 2000.
2. Greenhill L, Beyer DH, Finkleson J, et al. Guidelines and algorithms for the use of methylphenidate in children with attention defi cit/hyperactivity disorder. J Atten Disord. 2002;6(Suppl 1)S89-S100.
3. Aman MG. Stimulant drug effects in developmental disorders and hyperactivity toward a resolution of disparate fi ndings. J Autism Dev Disord. 1982;12(4):385-396.
4. Quintana H, Birmaher B, Stedge D, et al. Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord. 1995;25(3):283-294.
5. Handen BL, Johnson CR, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficithyperactivity disorder. J Autism Dev Disord. 2000;30(3):245-255.
6. Stigler KA, Desmond LA, Posey DJ, Wiegand RE, McDougle CJ. A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2004;14(1):49-56.
7. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry. 2005;62(11):1266-1274.
8. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-defi cit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894-921.
9. Posey DJ, Wiegand RE, Wilkerson J, Maynard M, Stigler KA, McDougle CJ. Open-label atomoxetine for attention-defi cit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006;16(5):599-610.
10. Jou RJ, Handen BL, Hardan AY. Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2005;15(2):325-330.
11. Troost PW, Steenhuis MP, Tuynaman-Qua HG, et al. Atomoxetine for attention-defi cit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study. J Child Adolesc Psychopharmacol. 2006;16(5):611-619.
12. Arnold LE, Aman MG, Cook AM, et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry. 2006;45(10):1196-1205.
13. Jaselskis CA, Cook EH, Fletcher KE Leventhal BL. Clonidine treatment of hyperactive and impulsive children with autistic disorders. J Clin Psychopharmacol. 1992;12(5):322-327.
14. Fankhauser MP, Karumanchi VC, German ML. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry. 1992;53(3):77-82.
15. Posey DJ, Puntney JI, Sasher TM, Kem DL, Mc-Dougle CJ. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol. 2004;14(2):233-241.
16. Handen BL, Sahl R, Hardan AY. Guanfacine in children with autism and/or intellectual disabilities. J Dev Behav Pediatr. 2008;29(4):303-308.
17. Scahill L, Aman MG, McDougle CJ, et al. A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006;16(5):589-598.
18. McDougle CJ, Stigler KA, Erickson CA, et al. Pharmacology of autism. Clin Neuroscience Res. 2006;6:179-188.
19. Erickson CA, Posey D J, Stigler KA, et al. Pharmacotherapy of autism and related disorders. Psychiatric Annals. 2007;37(7):490-500.
20. McDougle CJ, Holmes JP, Carlson DC, et al. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry. 1998;55(7):633-641.
21. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Risperidone in children with autism and serious behavioral problems. New Engl J Med. 2002;347(5):314-321.
22. Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004;114(5):634-641.
23. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry. 2005;162(7):1361-1369.
24. Hollander E, Wasserman S, Swanson EN, et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol, 2006;16(5):541-548.
25. Martin A, Koenig K, Scahill L, et al. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adol Psychopharmacol. 1999;9(2):99-107.
26. Findling RL, McNamara NK, Gracious BL, et al. Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol. 2004;14(2):287-294.
27. Corson AH, Barkenbus JE, Posey DJ, et al. A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. J Clin Psychiatry. 2004;65(11):1531-1536.
28. McDougle CJ, Kem DL, Posey DJ. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry. 2002;41(8):921-927.
29. Malone RP, Delaney MA, Hyman SB, et al. Ziprasidone in adolescents with autism: an openlabel pilot study. J Child Adolesc Psychopharmacol. 2007;17(6):779-790.
30. Valicenti-McDermott MR, Demb H. Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. J Child Adolesc Psychopharmacol. 2006;16(5):549-560.
31. Marcus RN, Owen R, Kamen L, et al. A placebocontrolled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adoles Psychiatry. 2009:48(11):1110-1119.
32. Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009;124(6):1533-1540.
33. Remington G, Sloman L, Konstantareas M., et al. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol. 2001;21(4):440-444.
34. Hollander E, Phillips A, Chaplin W, et al. A placebo controlled crossover trial of liquid fl uoxetine on repetitive behaviors in childhood adolescent autism. Neuropsychopharmacology. 2005;30(3):582-589.
35. McDougle CJ, Naylor ST, Cohen DJ, et al. A double-blind, placebo-controlled study of fl uvoxamine in adults with autistic disorders. Arch Gen Psychiatry. 1996;53(11):1001-1008.
36. McDougle CJ, Brodkin ES, Naylor ST, Carlson DC, Cohen DJ, Price LH. Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation. J Clin Psychopharmacol. 1998;18(1):62-66.
37. King B, Hollander E, Sikich, L, et al; STAART Psychopharmacology Network. Lack of efficacy in citalopram in children with autism spectrum disorders and high levels of repetitive behavior. Arch Gen Psychiatry. 2009;66(6):583-590.
38. Posey DJ, Erickson CA, McDougle CJ. Developing drugs for core social and communication impairment in autism. Child Adolesc Psychiatric Clin N Am. 2008;17(4):787-801.
39. Posey DJ, Stigler KA, Erickson CA, et al. A double-blind placebo-controlled study of D-cycloserine in children with autistic disorder. 55th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientifi c Proceedings. 2008;Abstract P3.53-83.
40. Chez MG, Burton Q, Dowling T, Chang M, Khanna P, Kramer C. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol. 2007;22(5):574-579